Schizophrenia has been primarily associated with dopamine dysfunction, and treatments
have been developed that target the dopamine pathway in the central nervous system …

Dopamine is an inhibitory neurotransmitter involved in the pathology of schizophrenia. The
revised dopamine hypothesis states that dopamine abnormalities in the mesolimbic and …

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia,
responsible for the onset of several long-term complications. Recent evidence suggests that …

Dopamine (DA) and glutamate neurotransmission are strongly implicated in schizophrenia
pathophysiology. While most studies focus on contributions of neurons that release only DA …

Dopamine partial agonism and functional selectivity have been innovative strategies in the
pharmacological treatment of schizophrenia and mood disorders and have shifted the …

Over the past 20 years, motor response inhibition and interference control have received
considerable scientific effort and attention, due to their important role in behavior and the …

The original definition of atypical antipsychotic drugs (APD) was drugs that are effective
against positive symptoms in schizophrenia with no or little extrapyramidal symptoms (EPS) …

The introduction of allosteric receptor–receptor interactions in G protein-coupled receptor
(GPCR) heteroreceptor complexes of the central nervous system (CNS) gave a new …

Research into the neurobiological processes that may lead to the onset of schizophrenia
places growing emphasis on the glutamatergic system and brain development. Preclinical …

Emerging researches point to a relevant role of postsynaptic density (PSD) proteins, such as
PSD-95, Homer, Shank, and DISC-1, in the pathophysiology of schizophrenia and autism …